

Figure S1. Overexpression of miR-383 inhibits the proliferation, migration and invasion of A549 cells. (A) Cell proliferation was determined using an MTT assay in A549 cells infected with lentivirus containing control miR (A549-Le/control) or miR-383 precursor (A549-Le/miR-383). (B) Cell migration was assessed using a wound healing assay. Scale bar, 200 μ m. (C) Cell invasion was assessed using Transwell assays. Scale bar, 50 μ m. Data are presented as the mean \pm standard deviation of three independent experiments. * P <0.05. miR, miRNA, microRNA; Le, lentiviral vector.




Figure S2. RT-qPCR and immunoblotting analysis of transfection efficiency. (A) RBM24 expression was determined by RT-qPCR and western blotting in A549 cells stably overexpressing miR-383. (B) RBM24 expression levels were determined by RT-qPCR and western blotting in A549/CDDP cells stably overexpressing miR-383. (C) RBM24 expression levels were determined by RT-qPCR in A549/CDDP cells transfected with RBM24 siRNA or nonsense control siRNA, as well as untransfected A549/CDDP cells. (D) miR-383 expression levels were determined by RT-qPCR in A549 cells transfected with miR-383 inhibitor or miRNA NC, as well as untransfected A549 cells. * $P < 0.05$. Data are presented as the mean \pm standard deviation of three independent experiments. RBM24, RNA binding motif protein 24; RT-qPCR, reverse transcription-quantitative PCR; siRNA, small interfering RNA; NC, nonsense control; miR, miRNA, microRNA; Le, lentiviral vector; A549/CDDP, cisplatin-resistant A549 cells.




Figure S3. RBM24-overexpressing A549 cells, miR-383-over-expressing A549/CDDP cells and their respective control cells were treated with or without 3 μ g/ml cisplatin for 24 h. The expression levels of RBM24 and cleaved caspase-3 were determined by western blotting (upper panel), and the relative expression of RBM24 and cleaved caspase-3 are shown as histograms (lower panel). RBM24, RNA binding motif protein 24; miR, microRNA.

